Glioblastoma targeted therapy: updated approaches from recent biological insights

Annals of Oncology

Volumn 28, Issue 7, 2017, Pages 1457-1472

  Touat, M ^a,b   Idbaih, A ^a,c   Sanson, M ^a,c   Ligon, K L ^d  

^a SORBONNE UNIVERSITÉ   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d Dana Farber/Brigham and Women's Cancer Center   (United States)

Author keywords

biomarkers; cancer genomics; glioma; personalized medicine; precision medicine; targeted therapies

Indexed keywords

ANTINEOPLASTIC AGENT; TUMOR MARKER;

ANIMAL; BRAIN TUMOR; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; EVIDENCE BASED MEDICINE; GENETICS; GLIOBLASTOMA; HUMAN; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 85032509927     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx106     Document Type: Review

References (222)

1. Ostrom, Q.T., Gittleman, H., Liao, P., et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol 16:Suppl 4 (2014), iv1–iv63.
2. Stupp, R., Mason, W.P., van den Bent, M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005), 987–996.
3. Rønning, P.A., Helseth, E., Meling, T.R., Johannesen, TB., A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme. Neuro Oncol 14 (2012), 1178–1184.
4. Stupp, R., Taillibert, S., Kanner, A.A., et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 314 (2015), 2535–2543.
5. Weller, M., van den Bent, M., Hopkins, K., et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 15 (2014), e395–e403.
6. Phillips, H.S., Kharbanda, S., Chen, R., et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9 (2006), 157–173.
7. Parsons, D.W., Jones, S., Zhang, X., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321 (2008), 1807–1812.
8. Network CGAR, Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 (2008), 1061–1068.
9. Noushmehr, H., Weisenberger, D.J., Diefes, K., et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17 (2010), 510–522.
10. Brennan, C.W., Verhaak, R.G., McKenna, A., et al. The somatic genomic landscape of glioblastoma. Cell 155 (2013), 462–477.
11. Frattini, V., Trifonov, V., Chan, J.M., et al. The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet 45 (2013), 1141–1149.
12. Louis, D.N., Perry, A., Reifenberger, G., et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131 (2016), 803–820.
13. Verhaak, R.G., Hoadley, K.A., Purdom, E., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17 (2010), 98–110.
14. Yoshihara, K., Wang, Q., Torres-Garcia, W., et al. The landscape and therapeutic relevance of cancer-associated transcript fusions. Oncogene 34 (2015), 4845–4854.
15. Ceccarelli, M., Barthel, F.P., Malta, T.M., et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164 (2016), 550–563.
16. Babu, R., Adamson, DC., Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma. Core Evid 7 (2012), 93–103.
17. Rohle, D., Popovici-Muller, J., Palaskas, N., et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340 (2013), 626–630.
18. Reardon, D.A., Wen, P.Y., Mellinghoff, IK., Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges. Neuro Oncol 16:Suppl 8 (2014), viii7–vii13.
19. Thomas, A.A., Brennan, C.W., DeAngelis, L.M., Omuro, AM., Emerging therapies for glioblastoma. JAMA Neurol 71 (2014), 1437–1444.
20. Gallego, O., Cuatrecasas, M., Benavides, M., et al. Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry. J Neurooncol 116 (2014), 413–419.
21. Di Stefano, A.L., Fucci, A., Frattini, V., et al. Detection, characterization and inhibition of FGFR-TACC fusions in IDH wild type glioma. Clin Cancer Res 21 (2015), 3307–3317.
22. Meyer, M., Reimand, J., Lan, X., et al. Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity. Proc Natl Acad Sci USA 112 (2015), 851–856.
23. Prados, M.D., Byron, S.A., Tran, N.L., et al. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol 17 (2015), 1051–1063.
24. Snuderl, M., Fazlollahi, L., Le, L.P., et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20 (2011), 810–817.
25. Lass, U., Nümann, A., von Eckardstein, K., et al. Clonal analysis in recurrent astrocytic, oligoastrocytic and oligodendroglial tumors implicates IDH1- mutation as common tumor initiating event. PLoS One, 7, 2012, e41298.
26. Little, S.E., Popov, S., Jury, A., et al. Receptor tyrosine kinase genes amplified in glioblastoma exhibit a mutual exclusivity in variable proportions reflective of individual tumor heterogeneity. Cancer Res 72 (2012), 1614–1620.
27. Sottoriva, A., Spiteri, I., Piccirillo, S.G., et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA 110 (2013), 4009–4014.
28. Johnson, B.E., Mazor, T., Hong, C., et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343 (2014), 189–193.
29. Patel, A.P., Tirosh, I., Trombetta, J.J., et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344 (2014), 1396–1401.
30. Francis, J.M., Zhang, C.Z., Maire, C.L., et al. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov 4 (2014), 956–971.
31. Nathanson, D.A., Gini, B., Mottahedeh, J., et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 343 (2014), 72–76.
32. Kim, H., Zheng, S., Amini, S.S., et al. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res 25 (2015), 316–327.
33. Kim, J., Lee, I.H., Cho, H.J., et al. Spatiotemporal evolution of the primary glioblastoma genome. Cancer Cell 28 (2015), 318–328.
34. Yap, T.A., Gerlinger, M., Futreal, P.A., et al. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med, 4, 2012, 127ps110.
35. Burrell, R.A., McGranahan, N., Bartek, J., Swanton, C., The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501 (2013), 338–345.
36. McGranahan, N., Favero, F., de Bruin, E.C., et al. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci Transl Med, 7, 2015, 283ra254.
37. Touat, M., Dhermain, F., André, F., Sanson, M., Adapting the drivers to the road: a new strategy for cancer evolution?. Ann Oncol 26 (2015), 827–829.
38. Wang, J., Cazzato, E., Ladewig, E., et al. Clonal evolution of glioblastoma under therapy. Nat Genet 48 (2016), 768–776.
39. Stommel, J.M., Kimmelman, A.C., Ying, H., et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318 (2007), 287–290.
40. Szerlip, N.J., Pedraza, A., Chakravarty, D., et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci USA 109 (2012), 3041–3046.
41. Stevens, M.M., Maire, C.L., Chou, N., et al. Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate. Nat Biotechnol 34 (2016), 1161–1167.
42. Nishikawa, R., Ji, X.D., Harmon, R.C., et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 91 (1994), 7727–7731.
43. Frederick, L., Wang, X.Y., Eley, G., James, CD., Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60 (2000), 1383–1387.
44. Maire, C.L., Ligon, KL., Molecular pathologic diagnosis of epidermal growth factor receptor. Neuro Oncol 16:Suppl 8 (2014), viii1–viii6.
45. Vivanco, I., Robins, H.I., Rohle, D., et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov 2 (2012), 458–471.
46. Schulte, A., Liffers, K., Kathagen, A., et al. Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ. Neuro Oncol 15 (2013), 1289–1301.
47. Sampson, J.H., Heimberger, A.B., Archer, G.E., et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28 (2010), 4722–4729.
48. Schuster, J., Lai, R.K., Recht, L.D., et al. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol 17 (2015), 854–861.
49. Reardon, D.A., Desjardins, A., Schuster, J., et al. IMCT-08ReACT: long-term survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma. Neuro Oncol, 17(Suppl 5), 2015, v109.
50. Weller, M., Butowski, N., Tran, D., et al. ATIM-03. ACT IV: an international, double-blind, phase 3 trial of rindopepimut in newly diagnosed, EGFRvIII-expressing glioblastoma. Neuro-Oncology 18:Suppl 6 (2016), vi17–vi18.
51. Phillips, A.C., Boghaert, E.R., Vaidya, K.S., et al. ABT-414, an antibody-drug conjugate targeting a tumor-selective EGFR epitope. Mol Cancer Ther 15 (2016), 661–669.
52. van den Bent, M., Gan, H., Lassman, A., et al. ACTR-07. Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified (EGFRamp), recurrent glioblastoma (rGBM). Neuro-Oncology, 18(Suppl 6), 2016, vi2.
53. Rich, J.N., Reardon, D.A., Peery, T., et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:1 (2004), 133–142.
54. Franceschi, E., Cavallo, G., Lonardi, S., et al. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer 96:7 (2007), 1047–1051.
55. van den Bent, M.J., Brandes, A.A., Rampling, R., et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 27 (2009), 1268–1274.
56. Neyns, B., Sadones, J., Joosens, E., et al. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol 20 (2009), 1596–1603.
57. Thiessen, B., Stewart, C., Tsao, M., et al. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother Pharmacol 65 (2010), 353–361.
58. Raizer, J.J., Abrey, L.E., Lassman, A.B., et al. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol 12 (2010), 95–103.
59. Yung, W.K., Vredenburgh, J.J., Cloughesy, T.F., et al. Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro Oncol 12 (2010), 1061–1070.
60. Uhm, J.H., Ballman, K.V., Wu, W., et al. Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. Int J Radiat Oncol Biol Phys 80 (2011), 347–353.
61. Lv, S., Teugels, E., Sadones, J., et al. Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab. Int J Oncol 41 (2012), 1029–1035.
62. Reardon, D.A., Nabors, L.B., Mason, W.P., et al. Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro Oncol 17 (2015), 430–439.
63. Sathornsumetee, S., Desjardins, A., Vredenburgh, J.J., et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol 12 (2010), 1300–1310.
64. Hasselbalch, B., Lassen, U., Hansen, S., et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol 12 (2010), 508–516.
65. Reardon, D.A., Groves, M.D., Wen, P.Y., et al. A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Clin Cancer Res 19 (2013), 900–908.
66. Reardon, D.A., Quinn, J.A., Vredenburgh, J.J., et al. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res 12 (2006), 860–868.
67. Doherty, L., Gigas, D.C., Kesari, S., et al. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 67 (2006), 156–158.
68. Reardon, D.A., Desjardins, A., Vredenburgh, J.J., et al. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol 96 (2010), 219–230.
69. Wen, P.Y., Chang, S.M., Lamborn, K.R., et al. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol 16 (2014), 567–578.
70. Kreisl, T.N., Lassman, A.B., Mischel, P.S., et al. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J Neurooncol 92 (2009), 99–105.
71. Peereboom, D.M., Ahluwalia, M.S., Ye, X., et al. NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. Neuro Oncol 15 (2013), 490–496.
72. Prados, M.D., Lamborn, K.R., Chang, S., et al. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol 8 (2006), 67–78.
73. Prados, M.D., Yung, W.K., Wen, P.Y., et al. Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. Cancer Chemother Pharmacol 61 (2008), 1059–1067.
74. Brown, P.D., Krishnan, S., Sarkaria, J.N., et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol 26 (2008), 5603–5609.
75. Krishnan, S., Brown, P.D., Ballman, K.V., et al. Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177. Int J Radiat Oncol Biol Phys 65 (2006), 1192–1199.
76. Prados, M.D., Chang, S.M., Butowski, N., et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 27 (2009), 579–584.
77. Peereboom, D.M., Shepard, D.R., Ahluwalia, M.S., et al. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol 98 (2010), 93–99.
78. Chakravarti, A., Wang, M., Robins, H.I., et al. RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. Int J Radiat Oncol Biol Phys 85 (2013), 1206–1211.
79. Clarke, J.L., Molinaro, A.M., Phillips, J.J., et al. A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma. Neuro Oncol 16 (2014), 984–990.
80. Seystahl, K., Wick, W., Weller, M., Therapeutic options in recurrent glioblastoma—an update. Crit Rev Oncol Hematol 99 (2016), 389–408.
81. Singh, D., Chan, J.M., Zoppoli, P., et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 337 (2012), 1231–1235.
82. Tabernero, J., Bahleda, R., Dienstmann, R., et al. Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. J Clin Oncol 33 (2015), 3401–3408.
83. Touat, M., Ileana, E., Postel-Vinay, S., et al. Targeting FGFR Signaling in Cancer. Clin Cancer Res 21 (2015), 2684–2694.
84. Lassman, A.B., Pugh, S.L., Gilbert, M.R., et al. Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). Neuro Oncol 17 (2015), 992–998.
85. Wen, P.Y., Yung, W.K., Lamborn, K.R., et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 12 (2006), 4899–4907.
86. Reardon, D.A., Dresemann, G., Taillibert, S., et al. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer 101 (2009), 1995–2004.
87. Razis, E., Selviaridis, P., Labropoulos, S., et al. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment. Clin Cancer Res 15 (2009), 6258–6266.
88. Dresemann, G., Weller, M., Rosenthal, M.A., et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J Neurooncol 96 (2010), 393–402.
89. Holdhoff, M., Supko, J.G., Gallia, G.L., et al. Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme. J Neurooncol 97 (2010), 241–245.
90. Li, Y., Li, A., Glas, M., et al. c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc Natl Acad Sci USA 108 (2011), 9951–9956.
91. Jahangiri, A., De Lay, M., Miller, L.M., et al. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res 19 (2013), 1773–1783.
92. Petterson, S.A., Dahlrot, R.H., Hermansen, S.K., et al. High levels of c-Met is associated with poor prognosis in glioblastoma. J Neurooncol 122 (2015), 517–527.
93. Johnson, J., Ascierto, M.L., Mittal, S., et al. Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma. J Transl Med, 13, 2015, 306.
94. Wen, P.Y., Schiff, D., Cloughesy, T.F., et al. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol 13 (2011), 437–446.
95. Chi, A.S., Batchelor, T.T., Kwak, E.L., et al. Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor. J Clin Oncol 30 (2012), e30–e33.
96. Le Rhun, E., Chamberlain, M.C., Zairi, F., et al. Patterns of response to crizotinib in recurrent glioblastoma according to ALK and MET molecular profile in two patients. CNS Oncol 4 (2015), 381–386.
97. Cloughesy, T., Finocchiaro, G., Belda-Iniesta, C., et al. Randomized, double-blind, placebo-controlled, multicenter phase II study of onartuzumab plus bevacizumab versus placebo plus bevacizumab in patients with recurrent glioblastoma: efficacy, safety, and hepatocyte growth factor and O(6)-methylguanine-DNA methyltransferase biomarker analyses. J Clin Oncol 35 (2016), 343–351.
98. Galanis, E., Buckner, J.C., Maurer, M.J., et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 23 (2005), 5294–5304.
99. Lassen, U., Sorensen, M., Gaziel, T.B., et al. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme. Anticancer Res 33 (2013), 1657–1660.
100. Ma, D.J., Galanis, E., Anderson, S.K., et al. A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Neuro Oncol 17 (2015), 1261–1269.
101. Pitz, M.W., Eisenhauer, E.A., MacNeil, M.V., et al. Phase II study of PX-866 in recurrent glioblastoma. Neuro Oncol 17 (2015), 1270–1274.
102. Massacesi, C., Di Tomaso, E., Urban, P., et al. PI3K inhibitors as new cancer therapeutics: implications for clinical trial design. Onco Targets Ther 9 (2016), 203–210.
103. Dias-Santagata, D., Lam, Q., Vernovsky, K., et al. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One, 6, 2011, e17948.
104. Chamberlain, MC., Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series. J Neurooncol 114 (2013), 237–240.
105. Hyman, D.M., Puzanov, I., Subbiah, V., et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 373 (2015), 726–736.
106. Hainsworth, J.D., Ervin, T., Friedman, E., et al. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer 116 (2010), 3663–3669.
107. Galanis, E., Anderson, S.K., Lafky, J.M., et al. Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. Clin Cancer Res 19 (2013), 4816–4823.
108. Reardon, D.A., Vredenburgh, J.J., Desjardins, A., et al. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol 101 (2011), 57–66.
109. Zustovich, F., Landi, L., Lombardi, G., et al. Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study. Anticancer Res 33 (2013), 3487–3494.
110. Lee, E.Q., Kuhn, J., Lamborn, K.R., et al. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro Oncol 14 (2012), 1511–1518.
111. Hottinger, A.F., Aissa, A.B., Espeli, V., et al. Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. Br J Cancer 110 (2014), 2655–2661.
112. Vousden, K.H., Lane, DP., p53 in health and disease. Nat Rev Mol Cell Biol 8 (2007), 275–283.
113. Sidransky, D., Mikkelsen, T., Schwechheimer, K., et al. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 355 (1992), 846–847.
114. Bögler, O., Huang, H.J., Cavenee, WK., Loss of wild-type p53 bestows a growth advantage on primary cortical astrocytes and facilitates their in vitro transformation. Cancer Res 55 (1995), 2746–2751.
115. Reifenberger, G., Liu, L., Ichimura, K., et al. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53 (1993), 2736–2739.
116. Duffy, M.J., Synnott, N.C., McGowan, P.M., et al. p53 as a target for the treatment of cancer. Cancer Treat Rev 40 (2014), 1153–1160.
117. Costa, B., Bendinelli, S., Gabelloni, P., et al. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor. PLoS One, 8, 2013, e72281.
118. Verreault, M., Schmitt, C., Goldwirt, L., et al. Preclinical efficacy of the MDM2 inhibitor RG7112 in MDM2-amplified and TP53 wild-type glioblastomas. Clin Cancer Res 22 (2016), 1185–1196.
119. Ohgaki, H., Kleihues, P., Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 100 (2009), 2235–2241.
120. Michaud, K., Solomon, D.A., Oermann, E., et al. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res 70 (2010), 3228–3238.
121. Wiedemeyer, W.R., Dunn, I.F., Quayle, S.N., et al. Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proc Natl Acad Sci USA 107 (2010), 11501–11506.
122. Cen, L., Carlson, B.L., Schroeder, M.A., et al. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro Oncol 14 (2012), 870–881.
123. Barton, K.L., Misuraca, K., Cordero, F., et al. PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma. PLoS One, 8, 2013, e77639.
124. Mir, S.E., De Witt Hamer, P.C., Krawczyk, P.M., et al. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell 18 (2010), 244–257.
125. De Witt Hamer, P.C., Mir, S.E., Noske, D., et al. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe. Clin Cancer Res 17 (2011), 4200–4207.
126. Toledo, C.M., Ding, Y., Hoellerbauer, P., et al. Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells. Cell Rep 13 (2015), 2425–2439.
127. Gupta, S.K., Mladek, A.C., Carlson, B.L., et al. Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts. Clin Cancer Res 20 (2014), 3730–3741.
128. Venere, M., Hamerlik, P., Wu, Q., et al. Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells. Cell Death Differ 21 (2014), 258–269.
129. Robins, H.I., Zhang, P., Gilbert, M., et al. ATCT-27NRG Oncology/RTOG 0929: a randomized phase I/II study of ABT-888IN combination with temozolomide in recurrent temozolomide resistant glioblastoma. Neuro Oncol, 17(Suppl 5), 2015, v7.
130. Yan, H., Parsons, D.W., Jin, G., et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 360 (2009), 765–773.
131. Hartmann, C., Meyer, J., Balss, J., et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118 (2009), 469–474.
132. Mondesir, J., Willekens, C., Touat, M., et al. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. J Blood Med 7 (2016), 171–180.
133. Turcan, S., Rohle, D., Goenka, A., et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483 (2012), 479–483.
134. Mellinghoff, I.K., Touat, M., Maher, E., et al. ACTR-46. AG120, a first-in-class mutant IDH1 inhibitor in patients with recurrent or progressive IDH1 mutant glioma: results from the phase 1 glioma expansion cohorts. Neuro-Oncology, 18(Suppl 6), 2016, vi12.
135. Schumacher, T., Bunse, L., Pusch, S., et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 512 (2014), 324–327.
136. Pellegatta, S., Valletta, L., Corbetta, C., et al. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. Acta Neuropathol Commun, 3, 2015, 4.
137. Xu, J., Sampath, D., Lang, F.F., et al. Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures. J Neurooncol 105 (2011), 241–251.
138. Cornago, M., Garcia-Alberich, C., Blasco-Angulo, N., et al. Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe. Cell Death Dis, 5, 2014, e1435.
139. Grasso, C.S., Tang, Y., Truffaux, N., et al. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat Med 21 (2015), 555–559.
140. Galanis, E., Jaeckle, K.A., Maurer, M.J., et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 27 (2009), 2052–2058.
141. Lee, E.Q., Puduvalli, V.K., Reid, J.M., et al. Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Clin Cancer Res 18 (2012), 6032–6039.
142. Puduvalli, V.K., Wu, J., Yuan, Y., Armstrong, T.S., et al. Brain Tumor Trials Collaborative Bayesian Adaptive Randomized Phase II trial of bevacizumab plus vorinostat versus bevacizumab alone in adults with recurrent glioblastoma (BTTC-1102). 2015 ASCO Annual Meeting. J Clin Oncol, 33, 2015.
143. Lee, E.Q., Reardon, D.A., Schiff, D., et al. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro Oncol 17 (2015), 862–867.
144. Cheng, Z., Gong, Y., Ma, Y., et al. Inhibition of BET bromodomain targets genetically diverse glioblastoma. Clin Cancer Res 19 (2013), 1748–1759.
145. de Vries, N.A., Hulsman, D., Akhtar, W., et al. Prolonged Ezh2 depletion in glioblastoma causes a robust switch in cell fate resulting in tumor progression. Cell Rep, 14, 2015 S2211–S1247.
146. Pastori, C., Kapranov, P., Penas, C., et al. The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation. Proc Natl Acad Sci USA 112 (2015), 8326–8331.
147. Bai, H., Harmancı, A.S., Erson-Omay, E.Z., et al. Integrated genomic characterization of IDH1-mutant glioma malignant progression. Nat Genet 48 (2016), 59–66.
148. Friedman, H.S., Prados, M.D., Wen, P.Y., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27 (2009), 4733–4740.
149. Kreisl, T.N., Kim, L., Moore, K., et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27 (2009), 740–745.
150. de Groot, J.F., Lamborn, K.R., Chang, S.M., et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 29 (2011), 2689–2695.
151. Neyns, B., Sadones, J., Chaskis, C., et al. Phase II study of sunitinib malate in patients with recurrent high-grade glioma. J Neurooncol 103 (2011), 491–501.
152. Kreisl, T.N., Smith, P., Sul, J., et al. Continuous daily sunitinib for recurrent glioblastoma. J Neurooncol 111 (2013), 41–48.
153. Hutterer, M., Nowosielski, M., Haybaeck, J., et al. A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07). Neuro Oncol 16 (2014), 92–102.
154. Batchelor, T.T., Duda, D.G., di Tomaso, E., et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28 (2010), 2817–2823.
155. Batchelor, T.T., Mulholland, P., Neyns, B., et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 31 (2013), 3212–3218.
156. Lee, E.Q., Kaley, T.J., Duda, D.G., et al. A multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma patients. Clin Cancer Res 21 (2015), 3610–3618.
157. Muhic, A., Poulsen, H.S., Sorensen, M., et al. Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme. J Neurooncol 111 (2013), 205–212.
158. Stupp, R., Hegi, M.E., Gorlia, T., et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 15 (2014), 1100–1108.
159. Nabors, L.B., Fink, K.L., Mikkelsen, T., et al. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Neuro Oncol 17 (2015), 708–717.
160. Wick, W., Puduvalli, V.K., Chamberlain, M.C., et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28 (2010), 1168–1174.
161. Taal, W., Oosterkamp, H.M., Walenkamp, A.M., et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15 (2014), 943–953.
162. Chinot, O.L., Wick, W., Mason, W., et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370 (2014), 709–722.
163. Gilbert, M.R., Dignam, J.J., Armstrong, T.S., et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370 (2014), 699–708.
164. Galanis, E., Anderson, S.K., Anastasiadis, P., et al. NCCTG N0872 (Alliance): a randomized placebo-controlled phase II trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma (GBM). 2015 ASCO Annual Meeting. J Clin Oncol, 33, 2015.
165. Duerinck, J., Du Four, S., Vandervorst, F., et al. Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma. J Neurooncol 128 (2016), 147–155.
166. Tanaka, S., Louis, D.N., Curry, W.T., et al. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?. Nat Rev Clin Oncol 10 (2013), 14–26.
167. Batchelor, T.T., Reardon, D.A., de Groot, J.F., et al. Antiangiogenic therapy for glioblastoma: current status and future prospects. Clin Cancer Res 20 (2014), 5612–5619.
168. Wick, W., Platten, M., Wick, A., et al. Current status and future directions of anti-angiogenic therapy for gliomas. Neuro Oncol 18 (2016), 315–328.
169. Wick, W., Brandes, A., Gorlia, T., et al. LB-05phase III trial exploring the combination of bevacizumab and lomustine in patients with first recurrence of a glioblastoma: the EORTC 26101 trial. Neuro Oncol, 17(Suppl 5), 2015, v1.
170. Sandmann, T., Bourgon, R., Garcia, J., et al. Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the AVAglio trial. J Clin Oncol 33 (2015), 2735–2744.
171. Hatterer, E., Davoust, N., Didier-Bazes, M., et al. How to drain without lymphatics? Dendritic cells migrate from the cerebrospinal fluid to the B-cell follicles of cervical lymph nodes. Blood 107 (2006), 806–812.
172. Iliff, J.J., Wang, M., Liao, Y., et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med, 4, 2012, 147ra111.
173. Louveau, A., Smirnov, I., Keyes, T.J., et al. Structural and functional features of central nervous system lymphatic vessels. Nature 523 (2015), 337–341.
174. Aspelund, A., Antila, S., Proulx, S.T., et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J Exp Med 212 (2015), 991–999.
175. Garon, E.B., Rizvi, N.A., Hui, R., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372 (2015), 2018–2028.
176. Robert, C., Schachter, J., Long, G.V., et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 372 (2015), 2521–2532.
177. Berghoff, A.S., Kiesel, B., Widhalm, G., et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol 17 (2015), 1064–1075.
178. Nduom, E.K., Wei, J., Yaghi, N.K., et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol 18 (2016), 195–205.
179. Fecci, P.E., Ochiai, H., Mitchell, D.A., et al. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res 13 (2007), 2158–2167.
180. Agarwalla, P., Barnard, Z., Fecci, P., et al. Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. J Immunother 35 (2012), 385–389.
181. Preusser, M., Lim, M., Hafler, D.A., et al. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol 11 (2015), 504–514.
182. Reardon, D.A., Gokhale, P.C., Klein, S.R., et al. Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model. Cancer Immunol Res 4 (2016), 124–135.
183. Reardon, D.A., Sampson, J.H., Sahebjam, S., et al. Safety and activity of nivolumab (nivo) monotherapy and nivo in combination with ipilimumab (ipi) in recurrent glioblastoma (GBM): updated results from checkmate-143. 2016 ASCO Annual Meeting. J Clin Oncol, 34, 2016.
184. Reardon, D.A., Kim, T.-M., Frenel, J.-S., et al. ATIM-35. Results of the phase IB KEYNOTE-028 multi-cohort trial of pembrolizumab monotherapy in patients with recurrent PD-L1-positive glioblastoma multiforme (GBM). Neuro-Oncology 18:Suppl 6 (2016), vi25–vi26.
185. Reardon, D., Kaley, T., Dietrich, J., et al. ATIM-04. Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab [DUR]) in patients with glioblastoma (GBM): results for cohort B (DUR monotherapy), bevacizumab (BEV) naïve patients with recurrent GBM. Neuro-Oncology, 18(Suppl 6), 2016, vi18.
186. Omuro, A., Vlahovic, G., Baehring, J., et al. ATIM-16. Nivolumab combined with radiotherapy with or without temozolomide in patients with newly diagnosed glioblastoma: results from phase 1 safety cohorts in checkmate 143. Neuro-Oncology, 18(Suppl 6), 2016, vi21.
187. Snyder, A., Makarov, V., Merghoub, T., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371 (2014), 2189–2199.
188. Van Allen, E.M., Miao, D., Schilling, B., et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350 (2015), 207–211.
189. Rizvi, N.A., Hellmann, M.D., Snyder, A., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
190. Le, D.T., Uram, J.N., Wang, H., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372 (2015), 2509–2520.
191. Bouffet, E., Larouche, V., Campbell, B.B., et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol 34 (2016), 2206–2211.
192. Ardon, H., Van Gool, S.W., Verschuere, T., et al. Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Immunol Immunother 61 (2012), 2033–2044.
193. Phuphanich, S., Wheeler, C.J., Rudnick, J.D., et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother 62 (2013), 125–135.
194. Bloch, O., Crane, C.A., Fuks, Y., et al. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol 16 (2014), 274–279.
195. Hdeib, A., Sloan, AE., Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax® platform in the treatment of glioblastoma multiforme. CNS Oncol 4 (2015), 63–69.
196. Phuphanich, S., Wheeler, C., Rudnick, J., et al. ATIM-25. Ten-year follow up with long term remission in patients with newly diagnosed glioblastoma (GBM) treated with ICT-107 vaccine (phase I). Neuro-Oncology, 18(Suppl 6), 2016, vi23.
197. Reardon, D., Peereboom, D., Nabors, B., et al. ATIM-11. Phase 2 trial of SL-701, a novel immunotherapy comprised of synthetic short peptides against GBM targets IL-13Rα2, EphA2, and survivin, in adults with second-line recurrent GBM: interim results. Neuro-Oncology, 18(Suppl 6), 2016, vi20.
198. Johnson, L.A., Scholler, J., Ohkuri, T., et al. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med, 7, 2015, 275ra222.
199. O'Rourke, D., Desai, A., Morrissette, J., et al. IMCT-15PILOT study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma. Neuro-Oncology 17:Suppl 5 (2015), v110–v111.
200. Rosenberg, S., Verreault, M., Schmitt, C., et al. Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors. Neuro Oncol, 2016, now160.
201. Mellinghoff, I.K., Wang, M.Y., Vivanco, I., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353 (2005), 2012–2024.
202. Haas-Kogan, D.A., Prados, M.D., Tihan, T., et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97 (2005), 880–887.
203. Touat, M., Duran-Peña, A., Alentorn, A., et al. Emerging circulating biomarkers in glioblastoma: promises and challenges. Expert Rev Mol Diagn 15 (2015), 1311–1323.
204. Pentsova, E.I., Shah, R.H., Tang, J., et al. Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid. J Clin Oncol 34 (2016), 2404–2415.
205. Klingler, S., Guo, B., Yao, J., et al. Development of resistance to EGFR-targeted therapy in malignant glioma can occur through EGFR-dependent and -independent mechanisms. Cancer Res 75 (2015), 2109–2119.
206. Hegi, M.E., Diserens, A.C., Bady, P., et al. Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib–a phase II trial. Mol Cancer Ther 10 (2011), 1102–1112.
207. Yu, C., Mannan, A.M., Yvone, G.M., et al. High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. Nat Biotechnol 34 (2016), 419–423.
208. Xiu, J., Piccioni, D., Juarez, T., et al. Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies. Oncotarget 7 (2016), 21556–21569.
209. Oberoi, R.K., Parrish, K.E., Sio, T.T., et al. Strategies to improve delivery of anticancer drugs across the blood–brain barrier to treat glioblastoma. Neuro Oncol 18 (2016), 27–36.
210. Lassman, A.B., Rossi, M.R., Raizer, J.J., et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res 11 (2005), 7841–7850.
211. de Vries, N.A., Buckle, T., Zhao, J., et al. Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Invest New Drugs 30 (2012), 443–449.
212. Dréan, A., Goldwirt, L., Verreault, M., et al. Blood–brain barrier, cytotoxic chemotherapies and glioblastoma. Expert Rev Neurother 16 (2016), 1285–1300.
213. Carpentier, A., Canney, M., Vignot, A., et al. Clinical trial of blood–brain barrier disruption by pulsed ultrasound. Sci Transl Med, 8, 2016, 343re342.
214. Andre, F., Mardis, E., Salm, M., et al. Prioritizing targets for precision cancer medicine. Ann Oncol 25 (2014), 2295–2303.
215. Aldape, K.D., Ballman, K., Furth, A., et al. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 63 (2004), 700–707.
216. Capper, D., Zentgraf, H., Balss, J., et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118 (2009), 599–601.
217. Capper, D., Weissert, S., Balss, J., et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20 (2010), 245–254.
218. Capper, D., Preusser, M., Habel, A., et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 122 (2011), 11–19.
219. Fischer, I., de la Cruz, C., Rivera, A.L., Aldape, K., Utility of chromogenic in situ hybridization (CISH) for detection of EGFR amplification in glioblastoma: comparison with fluorescence in situ hybridization (FISH). Diagn Mol Pathol 17 (2008), 227–230.
220. Nikiforova, M.N., Wald, A.I., Melan, M.A., et al. Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors. Neuro Oncol 18 (2016), 379–387.
221. Herbst, R.S., Gandara, D.R., Hirsch, F.R., et al. Lung master protocol (Lung-MAP)-a biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400. Clin Cancer Res 21 (2015), 1514–1524.
222. Ramkissoon, S.H., Bi, W.L., Schumacher, S.E., et al. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro Oncol 17 (2015), 1344–1355.